Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 2/20 | 0.36 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
| ▸ | KDM5A | P29375 | 1/20 | 0.30 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.30 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10811442 | 0.83 | — | — | |
| SCHEMBL6565536 | 0.75 | CYP1A2 (0.48) | NAAAKDM5AKDM4CPHF8KDM2A | |
| SCHEMBL12513177 | 0.75 | KDM5A (0.49) | PAOXACHEALDH1A1MAPTNAAA | |
| SCHEMBL9978410 | 0.75 | KDM5A (0.49) | PAOXACHEALDH1A1MAPTNAAA | |
| SCHEMBL8023937 | 0.75 | KDM5A (0.49) | PAOXACHEALDH1A1MAPTNAAA | |
| SCHEMBL26205812 | 0.74 | MAPT (0.37) | PAOXACHEALDH1A1MAPTNAAA | |
| SCHEMBL16239785 | 0.74 | PAOX (0.39) | TLR4PAOXACHENAAAKDM5A | |
| SCHEMBL9668398 | 0.74 | CYP1A2 (0.52) | NAAAKDM5AKDM4CPHF8KDM2A | |
| SCHEMBL22352762 | 0.72 | EPHX1 (0.41) | ALDH1A1ALOX5 | |
| SCHEMBL15177328 | 0.72 | MAPT (0.41) | PAOXACHEALDH1A1MAPTKDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010037025-A1 | New compounds, their preparation and use | MURRAY ANTHONY (DK) | 2001-11-01 | — | — | US | disclosed |
| EP-1077919-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999058486-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1999-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010037025-A1 | New compounds, their preparation and use | GPR119, SLC5A1, SLC5A2 | TLR4 2770/4885PAOX 742/4885ACHE 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.